The demand for dermatological drugs in Indonesia has been on the rise in recent years, driven by a growing middle class and increasing awareness about skincare.
Customer preferences: Indonesian consumers are becoming more conscious of their appearance and are willing to spend more on skincare products. The demand for dermatological drugs has increased as consumers seek effective solutions for various skin conditions, such as acne, eczema, and psoriasis. Additionally, there is a growing trend towards natural and organic skincare products, which has led to an increase in demand for dermatological drugs made from natural ingredients.
Trends in the market: The dermatological drugs market in Indonesia is expected to continue to grow in the coming years. The increasing prevalence of skin diseases, such as acne and eczema, is expected to drive demand for dermatological drugs. Additionally, the aging population in Indonesia is expected to create a growing demand for anti-aging skincare products. The increasing popularity of online shopping has also made it easier for consumers to purchase dermatological drugs, which is expected to further boost the market.
Local special circumstances: Indonesia has a large population of young people, which has contributed to the growth of the skincare market. Additionally, the country has a tropical climate, which can lead to various skin conditions, such as sunburn and heat rash. This has led to a higher demand for skincare products, including dermatological drugs.
Underlying macroeconomic factors: The Indonesian economy has been growing steadily in recent years, which has led to an increase in disposable income. This has allowed consumers to spend more on skincare products, including dermatological drugs. Additionally, the government has been investing in the healthcare sector, which has led to an improvement in healthcare infrastructure and an increase in access to healthcare services. This has contributed to the growth of the dermatological drugs market in Indonesia.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
